HC Wainwright Reiterates Buy Rating for FTH
HC Wainwright maintains a buy rating for FTH with a $60 price target, a 236.70% upside from the current price.
Key Points
- HC Wainwright reaffirms its buy rating for FTH, setting a $60 price target on June 22, 2026.
- HC Wainwright's $60 price target implies 236.70% upside from Faeth Therapeutics, Inc.'s ($FTH) current $17.82 share price.
- FTH shares traded at $17.82 on Monday, reflecting the market's current valuation.
- Analyst Patrick R. Trucchio from HC Wainwright initiated this rating, highlighting confidence in FTH's potential.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, HC Wainwright reiterated its buy rating for FTH, setting a price target of $60. Analyst Patrick R. Trucchio expressed continued confidence in the company's potential with this reaffirmation.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. initiated coverage on FTH with a buy rating and a $60 price target. This move by analyst Patrick R. Trucchio suggests a positive outlook for the company, as the target is significantly higher than the current trading price.
Faeth Therapeutics, Inc. Stock Down 47.3%
Shares of FTH traded at $17.82 on Monday. The stock's current valuation in the market reflects the ongoing analysis and expectations of future performance. The reiterated buy rating and $60 price target indicate that analysts see potential growth opportunities ahead.
$FTH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Bottom Line
HC Wainwright's reaffirmation of a buy rating for FTH, along with a $60 target, indicates confidence in the company's future prospects. Investors often track such ratings to gauge market sentiment and potential growth. It's important to remember that analyst ratings are forward-looking and based on current assessments.
Get Faeth Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $FTH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.